Join
Live feed
·
PRReleasevia Quantisnow
Bristol-Myers Squibb Company logo

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

ByQuantisnow·Wall Street's wire, on your screen.
BMY· Bristol-Myers Squibb Company
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMY (Bristol-Myers Squibb Company) and more on Quantisnow.